Voacangine (Iboga-type Indole Alkaloid · Ibogaine Precursor · Voacanga africana)

Compound	Voacangine
Chemical class	Alkaloid — Indole (Iboga-type monoterpene indole alkaloid; MIA)
CAS	83-34-1
Primary source	Voacanga africana (Voacanga; bark and seeds), Tabernaemontana spp.
Key applications	Ibogaine precursor (anti-addiction pharmaceutical synthesis); mild analgesic; cardiac glycoside-like; availability on request
Claim strength	Moderate
Typical form	Voacanga bark/seed extract; voacangine isolate (pharmaceutical ibogaine synthesis raw material)
Buy from Herbuno	Request availability and bulk pricing →

Name origin: From Voacanga africana (the primary botanical source). Voacangine is an iboga-type monoterpene indole alkaloid (MIA) — belonging to the same chemical family as ibogaine, with a related tetracyclic indole structure. Critically, voacangine is the primary semi-synthetic precursor for ibogaine — pharmaceutical-grade ibogaine used in addiction treatment research is predominantly synthesised from voacangine via deoxygenation of the 18-hydroxyl group. Botanical source and traditional use: Voacanga africana is a West African tree used in traditional medicine across Ghana, Ivory Coast, Nigeria, and neighbouring countries — for neurological conditions, impotence, cardiac support, and as a stimulant. The seeds have been reported to produce psychoactive effects at high doses. Traditional healers use bark preparations as stimulants and analgesics. Pharmaceutical significance — ibogaine precursor: Ibogaine (derived from Tabernanthe iboga) has attracted major research interest for treatment of opioid, methamphetamine, and alcohol use disorders — a single high dose of ibogaine is reported to interrupt addiction with effects lasting weeks to months. The supply of natural ibogaine is limited by the restricted distribution of Tabernanthe iboga; voacangine from Voacanga africana is the more commercially accessible MIA that enables ibogaine synthesis at scale. Multiple pharmaceutical companies are developing synthetic and semi-synthetic ibogaine derivatives using voacangine as a starting material. Commercial source: Not currently in the Herbuno catalogue. Contact Herbuno for availability assessment.

---

Evidence for Voacangine Applications

Analgesic activity: Voacangine demonstrates analgesic effects in animal pain models at doses below the psychoactive threshold. The mechanism likely involves serotonin receptor modulation (5-HT2 activity, shared with ibogaine) and mild opioid receptor interactions. The analgesic profile is considered milder than ibogaine but without ibogaine’s intense dissociative psychoactivity at lower doses. Claim strength: Moderate (animal).

Cardiac effects — positive inotropic: Voacangine has mild cardiac glycoside-like activity — positive inotropic effect at low doses via Na+/K+-ATPase modulation. Traditional West African use of Voacanga for cardiac support aligns with this pharmacology. At higher doses, cardiac toxicity risk emerges. The therapeutic window is narrow. Claim strength: Moderate (preclinical; traditional).

Ibogaine precursor value: The primary commercial value of voacangine is as a pharmaceutical synthesis raw material. Semi-synthetic ibogaine from voacangine costs significantly less than extraction from Tabernanthe iboga, enabling the growing ibogaine addiction treatment research programme. As Phase II ibogaine trials for opioid use disorder progress (Johns Hopkins, Stanford, NYU), demand for pharmaceutical-grade voacangine is increasing. Commercial pharmaceutical reference.

---

Frequently Asked Questions — Voacangine

Is voacangine psychoactive like ibogaine?
Voacangine has mild psychoactive properties at higher doses (it shares the iboga-type MIA scaffold responsible for ibogaine’s 5-HT2A agonism), but significantly lower potency than ibogaine. The psychoactive threshold for voacangine is substantially higher than the analgesic or cardiac dose, making low-dose administration pharmacologically feasible without the intense ibogaine dissociative experience. However, at doses approaching ibogaine-equivalent psychoactivity, voacangine also shares cardiac arrhythmia risk (QT prolongation) seen with ibogaine.

Why is Voacanga africana important for ibogaine supply?
Tabernanthe iboga grows only in the rainforests of Gabon and adjacent Central African countries, with slow growth and cultural restrictions on harvesting (iboga is sacred in the Bwiti religion of Gabon). Demand from addiction treatment researchers has created supply pressure. Voacanga africana is more widely distributed across West Africa, faster-growing, and less culturally restricted, providing a more sustainable and scalable ibogaine precursor. The voacangine → ibogaine semi-synthesis is well-established chemistry, making Voacanga cultivation the key enabler for scaling ibogaine addiction treatment.

Is voacangine regulated like ibogaine?
Regulatory status varies by jurisdiction. Voacangine itself is not a controlled substance in most markets (unlike ibogaine, which is Schedule I in the US). However, if voacangine is specifically sold for ibogaine synthesis, it may be regulated as a controlled substance precursor in some jurisdictions. For supplement contexts, voacangine is generally not restricted, but the mild psychoactive potential at higher doses means that clear dosing limits and appropriate regulatory framing are important in supplement formulation.

Are there ongoing clinical trials with voacangine?
No clinical trials with voacangine itself are currently registered. Clinical trial activity is focused on ibogaine (derived from voacangine synthesis) and novel ibogaine analogues (18-MC, tabernanthalog, noribogaine). Voacangine’s role is primarily as a pharmaceutical precursor rather than a clinical candidate in its own right, though its distinct pharmacological profile from ibogaine makes it scientifically interesting as an independent research subject.

Related compounds: Coronaridine, Tryptamine, Harmine, Strychnine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery